Skip to content

A Study on the effectiveness and adverse effect profile among patients treated with autoinoculation for multiple viral warts.

A Study on the effectiveness and adverse effect profile among patients treated with autoinoculation for multiple viral warts. - NIL

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2026/01/102139
Enrollment
34
Registered
2026-01-27
Start date
Unknown
Completion date
Unknown
Last updated
2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: O- Medical and Surgical Health Condition 2: B079- Viral wart, unspecified

Interventions

Intervention1: Autoinoculation for 1 year: autoinoculation of viral wart to non dominant arm, into a subdermal pocket to mount an immune response and observed after 4 weeks and 12 weeks Control Inter

Sponsors

Ashwini B
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: All diagnosed cases of warts more than five in number Patients with naive or recurrent or treatment unresponsive warts Patients willing to undergo the procedure of autoinoculation

Exclusion criteria

Exclusion criteria: Pregnancy and lactating mothers Patients with bleeding diathesis Patients with serious systemic illness Immunocompromised patients due to disease or drugs Patients who are not mentally fit so as to understand the nature of procedure and possible adverse effects.

Design outcomes

Primary

MeasureTime frame
To describe and determine the effectiveness of autoinoculation for the treatment of multiple viral warts at a tertiary health care center at 4 weeks and 12 weeks Timepoint: To describe and determine the effectiveness of autoinoculation for the treatment of multiple viral warts at a tertiary health care center at 4 weeks and 12 weeks

Secondary

MeasureTime frame
To describe & determine the adverse effects of autoinoculation for the treatment of multiple viral warts at a tertiary health care center at 4 weeks & 12 weeks Timepoint: To describe & determine the adverse effects of autoinoculation for the treatment of multiple viral warts at a tertiary health care center at 4 weeks & 12 weeks

Countries

India

Contacts

Public ContactASHWINI B

SREE UTHRADOM THIRUNAL ACADEMY OF MEDICAL SCIENCES

ashwinibabu@gmail.com9986410636

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 7, 2026